Petra C. Schuberth
Zurich, ZH, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Journal: Journal for immunotherapy of cancer
Published: June 18, 2023
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study.
Journal: Journal of hematology & oncology
Published: August 04, 2022
Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 09, 2020
Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 23, 2017
Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
Journal: Journal of translational medicine
Published: March 25, 2013
Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).
Journal: BMC cancer
Published: November 05, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026